UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Resistance to fluid shear stress is a conserved biophysical property of malignant cells

PloS one, 2012-12, Vol.7 (12), p.e50973

2012

Volltextzugriff (PDF)

Benchmarking multi-ancestry prostate cancer polygenic risk scores in a real-world cohort

PLoS computational biology, 2024-04, Vol.20 (4), p.e1011990-e1011990

2024

Volltextzugriff (PDF)

Complex implementation factors demonstrated when evaluating cost-effectiveness and monitoring racial disparities associated with [18F]DCFPyL PET/CT in prostate cancer men

Scientific reports, 2023-05, Vol.13 (1), p.8321-8321, Article 8321

2023

Volltextzugriff (PDF)

Prognostic value of neutrophil‐to‐lymphocyte ratio in patients with metastatic castration‐resistant prostate cancer receiving prostate‐specific membrane antigen targeted radionuclide therapy

The Prostate, 2023-10, Vol.83 (14), p.1351-1357

2023

Volltextzugriff (PDF)

Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks versus 2 weeks (SHORTER)

BMC cancer, 2023-08, Vol.23 (1), p.1-781, Article 781

2023

Volltextzugriff (PDF)

Prolyl-4-hydroxylase 3 (PHD3) expression is downregulated during epithelial-to-mesenchymal transition

PloS one, 2013-12, Vol.8 (12), p.e83021-e83021

2013

Volltextzugriff (PDF)

Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle?

Nature reviews. Urology, 2011-08, Vol.8 (8), p.428-439

2011

Volltextzugriff (PDF)

Antibody-drug conjugates for urothelial carcinoma

Urologic oncology, 2023-10, Vol.41 (10), p.420-428

2023

Volltextzugriff (PDF)

Successful outcome with eculizumab treatment in a patient with antiphospholipid syndrome presenting with an unusual thrombotic storm

Journal of thrombosis and thrombolysis, 2021-08, Vol.52 (2), p.597-600

2021

Volltextzugriff (PDF)

Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations

JCO precision oncology, 2020-04 (4), p.355-366

2020

Volltextzugriff (PDF)

Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225 Ac-J591

Journal of clinical oncology, 2024-03, Vol.42 (7), p.842-851

2024

Volltextzugriff (PDF)

Long-molecule scars of backup DNA repair in BRCA1- and BRCA2-deficient cancers

Nature (London), 2023-09, Vol.621 (7977), p.129-137

2023

Volltextzugriff (PDF)

An evaluation of the efficacy and safety of erdafitinib for the treatment of bladder cancer

Expert opinion on pharmacotherapy, 2020-05, Vol.21 (8), p.863-870

2020

Volltextzugriff (PDF)

Emerging Prostate-specific Membrane Antigen-based Therapeutics: Small Molecules, Antibodies, and Beyond

European urology focus, 2021-03, Vol.7 (2), p.254-257

2021

Volltextzugriff (PDF)

Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going

Cancer treatment reviews, 2024-06, Vol.127, p.102748, Article 102748

2024

Volltextzugriff (PDF)

Alterations in cancer cell mechanical properties after fluid shear stress exposure: a micropipette aspiration study

Cell health and cytoskeleton, 2015-01, Vol.7, p.25-35

2015

Volltextzugriff (PDF)

The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer

JNCI cancer spectrum, 2022-05, Vol.6 (3)

2022

Volltextzugriff (PDF)

Infantile Pasteurella multocida meningitis

IDCases, 2016-01, Vol.6, p.31-33

2016

Volltextzugriff (PDF)

Assessing barriers to prostate cancer clinical trial participation among Black and African Americans: A multi-perspective qualitative study

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.e13682-e13682

2024

Volltextzugriff (PDF)

Comparison of adverse event rate of prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) with antibody or small molecule ligand targeting vector

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.161-161

2024

Volltextzugriff (PDF)

Whole-food plant-based diet (WFPBD) to control weight and metabo-inflammation in overweight/obese men with prostate cancer (PC) receiving androgen deprivation therapy (ADT): A multi-center randomized control trial

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS5098-TPS5098

2023

Volltextzugriff (PDF)

Phase I results of a phase I/II study of pembrolizumab and AR signaling inhibitor (ARSI) with 225Ac-J591

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.181-181

2023

Volltextzugriff (PDF)

Randomized trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks vs. 2 weeks (SHORTER)

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.TPS400-TPS400

2023

Volltextzugriff (PDF)

Increased utilization of prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (PSMA-TRT) in African American (AA) patients at an academic medical center

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.36-36

2023

Volltextzugriff (PDF)

1 – 25 von 70

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(69)
Mit Volltextzugriff
(53)

Publikationsform

Artikel
(69)
Dissertationen
(1)

Sprache

Englisch
(70)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Resistance to fluid shear stress is a conserved biophysical property of malignant cells

Benchmarking multi-ancestry prostate cancer polygenic risk scores in a real-world cohort

Complex implementation factors demonstrated when evaluating cost-effectiveness and monitoring racial disparities associated with [18F]DCFPyL PET/CT in prostate cancer men

Prognostic value of neutrophil‐to‐lymphocyte ratio in patients with metastatic castration‐resistant prostate cancer receiving prostate‐specific membrane antigen targeted radionuclide therapy

Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks versus 2 weeks (SHORTER)

Prolyl-4-hydroxylase 3 (PHD3) expression is downregulated during epithelial-to-mesenchymal transition

Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle?

Antibody-drug conjugates for urothelial carcinoma

Successful outcome with eculizumab treatment in a patient with antiphospholipid syndrome presenting with an unusual thrombotic storm

Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations

Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225 Ac-J591

Long-molecule scars of backup DNA repair in BRCA1- and BRCA2-deficient cancers

An evaluation of the efficacy and safety of erdafitinib for the treatment of bladder cancer

The interplay of mutagenesis and ecDNA shapes urothelial cancer evolution

Emerging Prostate-specific Membrane Antigen-based Therapeutics: Small Molecules, Antibodies, and Beyond

Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going

Alterations in cancer cell mechanical properties after fluid shear stress exposure: a micropipette aspiration study

The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer

Infantile Pasteurella multocida meningitis

Assessing barriers to prostate cancer clinical trial participation among Black and African Americans: A multi-perspective qualitative study

Comparison of adverse event rate of prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) with antibody or small molecule ligand targeting vector

Whole-food plant-based diet (WFPBD) to control weight and metabo-inflammation in overweight/obese men with prostate cancer (PC) receiving androgen deprivation therapy (ADT): A multi-center randomized control trial

Phase I results of a phase I/II study of pembrolizumab and AR signaling inhibitor (ARSI) with 225Ac-J591

Randomized trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks vs. 2 weeks (SHORTER)

Increased utilization of prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (PSMA-TRT) in African American (AA) patients at an academic medical center

Suchergebnisse filtern